Quince Therapeutics, Inc. (QNCX)

Quince Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	115.98	5.81	6.21	20.75	44.58	69.72
Short-Term Investments	-	11.94	34.57	54.31	45.6	37.08
Cash & Short-Term Investments	115.98	17.75	40.78	75.06	90.18	106.8
Cash Growth	234.16%	-56.47%	-45.66%	-16.77%	-15.56%	-20.19%
Other Receivables	5	3.62	0.88	0.99	1	1.13
Receivables	5	3.62	0.88	0.99	1	1.13
Prepaid Expenses	0.77	0.89	0.99	1.17	1.2	1.48
Other Current Assets	1.66	0.63	1.38	0.21	1.36	2.27
Total Current Assets	123.41	22.9	44.04	77.44	93.75	111.67
Property, Plant & Equipment	0.51	1.05	0.81	0.62	0.68	1.43
Long-Term Investments	0.08	0.08	0.08	0.08	3.58	19.93
Goodwill	-	-	-	17.63	-	-
Other Intangible Assets	-	67.82	60.05	63.67	5.9	-
Other Long-Term Assets	-	1.68	9.51	8.47	-	0.19
Total Assets	124	93.52	114.48	167.9	103.91	133.23

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	4.64	2.22	2.9	2.03	0.57	4.91
Accrued Expenses	3.5	10.29	3.97	3.12	1.86	8.39
Current Portion of Long-Term Debt	-	18.03	-	-	-	-
Current Portion of Leases	-	0.12	0.1	0.06	0.45	0.74
Other Current Liabilities	0.36	12.58	0.31	4.36	0.19	0.18
Total Current Liabilities	8.5	43.23	7.28	9.57	3.07	14.22
Long-Term Debt	-	-	14.32	13.43	-	-
Long-Term Leases	-	0.33	0.39	0.32	-	0.42
Long-Term Deferred Tax Liabilities	-	-	4.96	5.3	0.25	-
Other Long-Term Liabilities	7.01	85.68	57.38	54.19	-	-
Total Liabilities	15.51	129.24	84.33	82.82	3.32	14.64

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	0	0.06	0.04	0.04	0.04	0.03
Additional Paid-In Capital	460.45	418.93	406.61	401.64	389.11	355.23
Retained Earnings	-500.03	-460.45	-376.47	-319.64	-288.26	-236.6
Comprehensive Income & Other	4.26	5.75	-0.04	3.05	-0.29	-0.08
Total Common Equity	-35.32	-35.71	30.15	85.08	100.59	118.59
Shareholders' Equity	108.49	-35.71	30.15	85.08	100.59	118.59
Total Liabilities & Equity	124	93.52	114.48	167.9	103.91	133.23

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	-	18.47	14.81	13.81	0.45	1.16
Net Cash (Debt)	115.98	-0.72	25.97	61.25	89.73	105.64
Net Cash Growth	573.52%	-	-57.59%	-31.74%	-15.06%	-20.79%
Net Cash Per Share	64.97	-2.87	120.07	328.95	535.74	710.94
Filing Date Shares Outstanding	1.02	0.82	0.22	0.22	0.18	0.15
Total Common Shares Outstanding	1.02	0.28	0.22	0.21	0.18	0.15
Working Capital	114.91	-20.33	36.76	67.87	90.68	97.45
Book Value Per Share	-34.73	-128.18	137.02	395.99	556.74	788.62
Tangible Book Value	-35.32	-103.53	-29.9	3.79	94.69	118.59
Tangible Book Value Per Share	-34.73	-371.58	-135.90	17.62	524.09	788.62
Machinery	1.31	1.37	0.89	0.68	0.43	0.61
Leasehold Improvements	0.04	0.04	0.03	0.04	0.02	0.06

SEC Filings: 10-K · 10-Q

Data Source: S&P Global Market Intelligence Last updated: May 11, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Sep 1, 2026

Data Sources Report a data error